COURSE: COPD
TRENDS IN DIAGNOSIS
& TREATMENTS

Organisers:
Prof. Peter J. Barnes &
Dr. Richard Russell

www.copdcourse.com
COPD is a major global health problem, now affecting over 10% of people over 45 years and being the third most common cause of mortality in high-income countries. COPD exacerbations are also one of the common causes for hospital admissions. While the main cause of COPD is smoking in Western countries, in developing countries COPD is commonly seen in non-smokers and is caused by the exposure to biomass fuel in homes.

We now have a better understanding of the underlying mechanisms of COPD, which involves chronic inflammation of the peripheral airways and lung parenchyma, acceleration of the normal ageing process and chronic bacterial colonisation of the airways. A better understanding of the disease has identified new therapeutic targets.

Long-acting bronchodilators have proved to be the most useful treatments for COPD at present, and a combination of a Long acting Muscarinic Antagonist (LAMA) with a Long Acting β2-Agonist (LABA) provides optimal bronchodilatation. We still need treatments that target the underlying inflammatory disease, but corticosteroids are only useful in a few patients because of corticosteroid resistance, and the phosphodiesterase 4 inhibitor roflumilast is limited by its side effects. There appear to be distinct phenotypes of COPD patients that may benefit from these different anti-inflammatory treatments.

Most patients with COPD have comorbidities, and these may be due to shared pathogenetic mechanisms with COPD, such as accelerate ageing and chronic inflammation. The presence of comorbidities may also affect management.

The National Heart and Lung Institute (NHLI) at Imperial College and its associated Royal Brompton Hospital is the largest centre for COPD research in Europe, with some of the most highly cited investigators in the world. We take a multidisciplinary approach to our research and link basic research with clinical measurements and studies.

Prof. Peter J. Barnes

Dr. Richard Russel
COPD is a major global health problem, now affecting over 10% of people over 45 years and being the third most common cause of mortality in high-income countries. COPD exacerbations are also one of the common causes for hospital admissions. While the main cause of COPD is smoking in Western countries, in developing countries COPD is commonly seen in non-smokers and is caused by the exposure to biomass fuel in homes.

We now have a better understanding of the underlying mechanisms of COPD, which involves chronic inflammation of the peripheral airways and lung parenchyma, acceleration of the normal ageing process and chronic bacterial colonisation of the airways. A better understanding of the disease has identified new therapeutic targets.

Long-acting bronchodilators have proved to be the most useful treatments for COPD at present, and a combination of a Longacting Muscarinic Antagonist (LAMA) with a Long Acting \( \beta \)-Agonist (LABA) provides optimal bronchodilatation. We still need treatments that target the underlying inflammatory disease, but corticosteroids are only useful in a few patients because of corticosteroid resistance, and the phosphodiesterase 4 inhibitor roflumilast is limited by its side effects. There appear to be distinct phenotypes of COPD patients that may benefit from these different anti-inflammatory treatments.

Most patients with COPD have comorbidities, and these may be due to shared pathogenetic mechanisms with COPD, such as accelerate ageing and chronic inflammation. The presence of comorbidities may also affect management.

The National Heart and Lung Institute (NHLI) at Imperial College and its associated Royal Brompton Hospital is the largest centre for COPD research in Europe, with some of the most highly cited investigators in the world. We take a multidisciplinary approach to our research and link basic research with clinical measurements and studies.
Venue:
The Royal College of Physicians
11 St. Andrews Place, Regent’s Park
London NW1 4LE

Hotel:
Several hotels in the area can provide accommodation. Hotel requirements are to be arranged by the delegate.

Lunch:
Lunches will be provided during the course at the Royal College of Physicians.

Registration fee:
Early bird: 575 EURO
After 1st June 2019: 675 EURO

COPD Course Secretariat:
European Conference & Incentive Services
C/. Francesc Carbonell 36
08034 Barcelona (Spain)
www.copdcourse.com
T. +34 93 206 04 04
For registration and information, please contact Lilian Palanca: info@copdcourse.com

COPD Course Dinner on 10th October 2019
Dinner Registration: 72,00 GBP (equal to 84,00€)

Cancellation terms after Registration:
In case of cancellation, following terms apply:
Cancellation made 3 months prior to the event: 50% of the registration fee will be refunded.
Cancellation made 1 month prior to the event: 25% of the registration fee will be refunded.
Cancellation made 30 days or less prior to the event: No refund will be made.
A cancellation handling fee of 35€ will be applied.